CRISPR Therapeutics Stock News

Shares of Crispr Therapeutics Inc. CRSP, +1.93% were down 5.8% in premarket trading on Wednesday, the day after the company announced data from a Phase 1 clinical trial for its CAR-T cell therapy cand

The stock price of Crispr Therapeutics AG (NASDAQ: CRSP) fell by over 6% today. This is why it happened.

Hint: it doesn't really matter what kind of market it is.

-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis-

A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Friday.

Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?

CRISPR Therapeutics stock is now down roughly 33% across 2021's trading.

-Management to host conference call and webcast on October 12th at 4:30 p.m. ET-

CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni Presents at Chardan's 5th Annual Genetic Medicines Conference Call Transcript

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $111.93, marking a +1.57% move from the previous day.

A stock market that soured on biotech stocks in general is presenting some bargain opportunities.

Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber congenital amaurosis 10 (LCA10), a CEP290-

Reasons To Buy Vertex Below $200

These top seven stocks among Cathie Wood's top holdings are ones investors may be enticed to consider right now. The post 7 Cathie Wood Stocks Every Growth Investor Needs In Their Portfolio appeared f

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $117.81, moving +0.48% from the previous trading session.